Pretreatment method and system for enhancing transdermal drug delivery

• US 20050106226A1
• Filed: 10/21/2004
• Published: 05/19/2005
• Est. Priority Date: 10/24/2003
• Status: Abandoned Application

• Current Assignee: ALZA Corporation (Johnson & Johnson)
• Original Assignee: ALZA Corporation (Johnson & Johnson)
• Inventors: Cormier, Michel J.N., Nyam, Kofi, Johnson, Juanita, Lin, WeiQi
• Application Number:
  US10/970,901
• Publication Number:
  US 20050106226A1
• Time in Patent Office: Days
• US Class Current: 424/449
• CPC Class Codes: A61K 9/0021 Intradermal administration, e.g. through microneedle arrays, needleless injectors mechanical aspects A61M
• CPC Class Codes: A61K 9/703 characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
• CPC Class Codes: A61K 9/7084 Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
• CPC Class Codes: A61M 2037/0023 Drug applicators using microneedles
• CPC Class Codes: A61M 37/0015 by using microneedles

Abstract

A drug delivery system for delivering a biologically active agent through the skin of a patient comprises (i) a pretreatment patch adapted to be placed on the patient'"'"'s skin, the pretreatment patch having a backing membrane and a microprojection array, the microprojection array being adhered to the backing membrane, the microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, the pretreatment patch including a skin template that remains on the patient'"'"'s skin after the pretreatment patch is applied to and removed from the patient'"'"'s skin, and (ii) a gel patch having a top and bottom surface, the gel patch including a reservoir containing a hydrogel formulation, the gel patch having a skin contact area in the range of approximately 0.5-30 cm².

Claims

1. A drug delivery system for delivering a biologically active agent through the skin of a patient, comprising:

a pretreatment patch adapted to be placed on the patient'"'"'s skin, said pretreatment patch having a backing membrane ring and a microprojection array, said microprojection array being adhered to said backing membrane ring, said microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, said pretreatment patch including a release liner ring that is removably secured to said backing membrane and a skin adhesive ring that is adhered to said release liner ring, said release liner ring and said skin adhesive ring being adapted to form a skin template on the patient'"'"'s skin after said pretreatment patch is applied to and removed from the patient'"'"'s skin; and

a gel patch having a top and bottom surface, said gel patch including a reservoir containing a hydrogel formulation, said gel patch having a skin contact area in the range of approximately 0.5-30 cm², said gel patch being adapted to be disposed on said skin template.

2. The delivery system of claim 1, wherein said gel patch includes a formulation membrane that is disposed proximate said gel patch reservoir, said formulation membrane being adapted to inhibit migration of enzymes into said hydrogel formulation.

3. The delivery system of claim 2, wherein said formulation membrane is adapted to inhibit migration of bacteria into said hydrogel formulation.

4. The delivery system of claim 1, wherein said pretreatment patch includes a polymeric membrane ring that is disposed between said release liner ring and said skin adhesive ring.

5. The delivery system of claim 4, wherein said skin template comprises said release liner ring, polymeric membrane ring and skin adhesive ring.

6. The delivery system of claim 1, wherein said pretreatment patch includes at least one release tag in communication with said release liner ring.

7. The delivery system of claim 1, wherein said pretreatment patch includes a polymeric membrane disposed between said backing membrane ring and said microprojection array.

8. The delivery system of claim 1, wherein said microprojection array has a microprojection density in the range of 10-2000 microprojections/cm².

9. The delivery system of claim 1, wherein said microprojection array provides a pretreated skin area in the range of approximately 0.5-30 cm² after said pretreatment patch is applied to the skin of the patient.

10. The delivery system of claim 1, wherein said pretreated skin area is substantially equal to said gel patch skin contact area.

11. The delivery system of claim 1, wherein said pretreated skin area is greater than said gel patch skin contact area.

12. The delivery system of claim 1, wherein said hydrogel formulation comprises a water-based hydrogel.

13. The delivery system of claim 12, wherein said hydrogel formulation comprises a polymeric material.

14. The delivery system of claim 13, wherein said polymeric material comprises a cellulose derivative.

15. The delivery system of claim 13, wherein said polymeric material is selected from the group consisting of EHEC, CMC, poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethylmethacrylate), poly(n-vinyl pyrolidone) and mixtures thereof.

16. The delivery system of claim 1, wherein said hydrogel formulation includes at least one biologically active agent.

17. The delivery system of claim 16, wherein said biologically active agent is selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids and polysaccharides.

18. The delivery system of claim 16, wherein said biologically active agent is selected from the group consisting of a leutinizing hormone releasing hormone (LHRH), LHRH analogs, vasopressin, desmopressin, corticotropin (ACTH), ACTH analogs, including ACTH (1-24), calcitonin, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, interferon alpha, interferon beta, interferon gamma, erythropoietin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin-10 (IL-10), glucagon, growth hormone releasing hormone (GHRH), growth hormone releasing factor (GHRF), insulin, insultropin, calcitonin, octreotide, endorphin, TRN, N-[[(s)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide, liprecin, pituitary hormones, including HGH, HMG and desmopressin acetate, follicle luteoids, aANF, growth factors, including growth factor releasing factor (GFRF), bMSH, GH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor releasing factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH), erythropoietin, epoprostenol (platelet aggregation inhibitor), glucagon, HCG, hirulog, hyaluronidase, interferon, interleukins, menotropins (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, desmopressin, ANP, ANP clearance inhibitors, BNP, VEGF, angiotensin II antagonists, antidiuretic hormone agonists, bradykinn antagonists, ceredase, CSI'"'"'s, calcitonin gene related peptide (CGRP), enkephalins, FAB fragments, IgE peptide suppressors, IGF-1, neurotrophic factors, colony stimulating factors, parathyroid hormone and agonists, parathyroid hormone antagonists, prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vasopressin antagonists analogs, alpha-1 antitrypsin (recombinant), TGF-beta, and mixtures thereof.

19. The delivery system of claim 1, wherein said hydrogel formulation includes at least one pathway patency modulator.

20. The delivery system of claim 1, wherein said hydrogel formulation includes a vasoconstrictor.

21. The delivery system of claim 1, wherein said delivery system includes an applicator retainer that is adapted to cooperate with a pretreatment patch applicator.

22. The delivery system of claim 21, wherein said retainer includes a pretreatment patch seat adapted to receive said pretreatment patch.

23. The delivery system of claim 22, wherein said backing membrane ring includes adhesive tabs adapted to adhere to said pretreatment patch seat.

24. The delivery system of claim 23, wherein said pretreatment patch includes a supplemental adhesive ring that is adapted to cooperate with said skin adhesive ring, said supplemental adhesive ring being disposed between said release liner ring and said skin adhesive ring.

25. The delivery system of claim 23, wherein said retainer includes a pretreatment patch ring that is adapted to receive said pretreatment patch adhesive tabs during application of said pretreatment patch to the patient'"'"'s skin, whereby said pretreatment patch is removable from the patient'"'"'s skin by removing said retainer therefrom and whereby said skin template is disposed on the patient'"'"'s skin.

26. The delivery system of claim 22, wherein said backing membrane ring includes a plurality of slots disposed proximate the periphery of said backing membrane ring and a plurality of break-away tabs adapted to cooperate with said pretreatment patch seat.

27. The delivery system of claim 26, wherein said retainer includes a pretreatment patch member having a plurality of posts that are adapted to engage said pretreatment patch slots during application of said pretreatment patch to the patient'"'"'s skin, whereby said pretreatment patch is removable from the patient'"'"'s skin by removing said retainer therefrom and whereby said skin template is disposed on the patient'"'"'s skin.

28. A pretreatment device for pre-treating a patient'"'"'s skin, comprising:

a backing membrane ring; and

a microprojection array, said microprojection array being adhered to said backing membrane ring, said microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, said pretreatment patch including a release liner ring that is removably secured to said backing membrane and a skin adhesive ring that is adhered to said release liner ring, said release liner ring and said skin adhesive ring being adapted to form a skin template on the patient'"'"'s skin after said pretreatment patch is applied to and removed from the patient'"'"'s skin.

29. The pretreatment device of claim 28, wherein said pretreatment patch includes a polymeric membrane ring that is disposed between said release liner ring and said skin adhesive ring.

30. The pretreatment device of claim 29, wherein said skin template comprises said release liner ring, polymeric membrane ring and skin adhesive ring.

31. The pretreatment device of claim 28, wherein said pretreatment patch includes at least one release tag in communication with said release liner ring.

32. The pretreatment device of claim 28, wherein said pretreatment patch includes a polymeric membrane disposed between said backing membrane ring and said microprojection array.

33. The pretreatment device of claim 28, wherein said microprojection array has a microprojection density in the range of 10-2000 microprojections/cm².

34. The pretreatment device of claim 28, wherein said microprojection array provides a treated skin area in the range of approximately 0.5-30 cm² after said pretreatment patch is applied to the skin of the patient.

35. A method for delivering a biologically active agent through the skin of a patient, comprising the steps of:

providing a pretreatment patch adapted to be placed on the patient'"'"'s skin, said pretreatment patch having a backing membrane ring and a microprojection array, said microprojection array being adhered to said backing membrane ring, said microprojection array including a plurality of microprojections adapted to pierce the stratum corneum of the patient, said pretreatment patch including a release liner ring that is removably secured to said backing membrane and a skin adhesive ring that is adhered to said release liner ring, said release liner ring and said skin adhesive ring being adapted to form a skin template on the patient'"'"'s skin after said pretreatment patch is applied to and removed from the patient'"'"'s skin;

providing a gel patch having a top and bottom surface, said gel patch including a reservoir containing a hydrogel formulation, said gel patch having a skin contact area in the range of approximately 0.5-30 cm²;

applying said pretreatment patch to the patient'"'"'s skin, whereby said microprojections pierce said stratum corneum of the patient to provide a pretreated skin area having a plurality of microslits and whereby said skin template adheres to the patient'"'"'s skin;

removing said pretreatment patch from the patient'"'"'s skin; and

applying said gel patch to said pretreated skin area, said gel patch being positioned over said skin template, whereby said hydrogel formulation is released from said reservoir and migrates into and through said microslits formed in said stratum corneum by said pretreatment patch.

36. The method of claim 35, wherein said gel patch includes a formulation membrane that is disposed proximate said gel patch reservoir, said formulation membrane being adapted to inhibit migration of enzymes into said hydrogel formulation.

37. The method of claim 36, wherein said formulation membrane is adapted to inhibit migration of bacteria into said hydrogel formulation.

38. The method of claim 35, wherein said pretreatment patch includes a polymeric membrane ring that is disposed between said release liner ring and said skin adhesive ring.

39. The method of claim 38, wherein said skin template comprises said release liner ring, polymeric membrane ring and skin adhesive ring.

40. The method of claim 35, wherein said pretreatment patch includes at least one release tag in communication with said release liner ring.

41. The method of claim 35, wherein said pretreatment patch includes a polymeric support membrane disposed between said backing membrane ring and said microprojection array.

42. The method of claim 35, wherein said microprojection array has a microprojection density in the range of 10-2000 microprojections/cm².

43. The method of claim 35, wherein said a pretreated skin area is in the range of approximately 0.5-30 cm².

44. The method of claim 35, wherein said pretreated skin area is substantially equal to said gel patch skin contact area.

45. The method of claim 35, wherein said pretreated skin area is greater than said gel patch skin contact area.

46. The method of claim 35, wherein said hydrogel formulation comprises a water-based hydrogel.

47. The method of claim 46, wherein said hydrogel formulation comprises a polymeric material.

48. The method of claim 47, wherein said polymeric material comprises a cellulose derivative.

49. The method of claim 47, wherein said polymeric material is selected from the group consisting of EHEC, CMC, poly(vinyl alcohol), poly(ethylene oxide), poly(2-hydroxyethylmethacrylate), poly(n-vinyl pyrolidone) and mixtures thereof.

50. The method of claim 35, wherein said hydrogel formulation includes at least one biologically active agent.

51. The method of claim 50, wherein said biologically active agent is selected from the group consisting of polypeptides, proteins, oligonucleotides, nucleic acids and polysaccharides.

52. The method of claim 50, wherein said biologically active agent is selected from the group consisting of a leutinizing hormone releasing hormone (LHRH), LHRH analogs, vasopressin, desmopressin, corticotropin (ACTH), ACTH analogs, including ACTH (1-24), calcitonin, parathyroid hormone (PTH), vasopressin, deamino [Val4, D-Arg8] arginine vasopressin, interferon alpha, interferon beta, interferon gamma, erythropoietin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin-10 (IL-10), glucagon, growth hormone releasing hormone (GHRH), growth hormone releasing factor (GHRF), insulin, insultropin, calcitonin, octreotide, endorphin, TRN, N-[[(s)-4-oxo-2-azetidinyl]carbonyl]-L-histidyl-L-prolinamide, liprecin, pituitary hormones, including HGH, HMG and desmopressin acetate, follicle luteoids, aANF, growth factors, including growth factor releasing factor (GFRF), bMSH, GH, somatostatin, bradykinin, somatotropin, platelet-derived growth factor releasing factor, asparaginase, bleomycin sulfate, chymopapain, cholecystokinin, chorionic gonadotropin, corticotropin (ACTH), erythropoietin, epoprostenol (platelet aggregation inhibitor), glucagon, HCG, hirulog, hyaluronidase, interferon, interleukins, menotropins (urofollitropin (FSH) and LH), oxytocin, streptokinase, tissue plasminogen activator, urokinase, vasopressin, desmopressin, ANP, ANP clearance inhibitors, BNP, VEGF, angiotensin II antagonists, antidiuretic hormone agonists, bradykinn antagonists, ceredase, CSI'"'"'s, calcitonin gene related peptide (CGRP), enkephalins, FAB fragments, IgE peptide suppressors, IGF-1, neurotrophic factors, colony stimulating factors, parathyroid hormone and agonists, parathyroid hormone antagonists, prostaglandin antagonists, pentigetide, protein C, protein S, renin inhibitors, thymosin alpha-1, thrombolytics, TNF, vasopressin antagonists analogs, alpha-1 antitrypsin (recombinant), TGF-beta, and mixtures thereof.

53. The method of claim 35, wherein said hydrogel formulation includes at least one pathway patency modulator.

54. The method of claim 35, wherein said hydrogel formulation includes a vasoconstrictor.

55. The method of claim 35, wherein said method includes providing an applicator retainer that is adapted to cooperate with a retainer patch applicator.

56. The method of claim 55, wherein said retainer includes a pretreatment patch seat adapted to receive said pretreatment patch.

57. The method of claim 56, wherein said backing membrane ring includes adhesive tabs adapted to adhere to said pretreatment patch seat.

58. The method of claim 57, wherein said pretreatment patch includes a supplemental adhesive ring that is adapted to cooperate with said skin adhesive ring, said supplemental adhesive ring being disposed between said release liner ring and said skin adhesive ring.

59. The method of claim 55, wherein said retainer includes a pretreatment patch ring that is adapted to receive said pretreatment patch adhesive tabs during said application of said pretreatment patch to the patient'"'"'s skin, whereby said pretreatment patch is removable from the patient'"'"'s skin by removing said retainer therefrom and whereby said skin template is adhered on the patient'"'"'s skin.

60. The method of claim 55, wherein said backing membrane ring includes a plurality of slots disposed proximate the periphery of said backing membrane ring and a plurality of break-away tabs that are adapted to cooperate with said pretreatment patch seat.

61. The method of claim 60, wherein said retainer includes a pretreatment patch member having a plurality of posts that are adapted to engage said pretreatment patch slots during said application of said pretreatment patch to the patient'"'"'s skin, whereby said pretreatment patch is removable from the patient'"'"'s skin by removing said retainer therefrom and whereby said skin template is adhered to the patient'"'"'s skin.

62. The method of claim 55, including the step of delivering up to 50 mg per day of said biologically active agent.

63. The method of claim 62, wherein said delivery step comprises zero-order delivery.)